Get started
Author

Scott Kristian Jew

Observed name: Scott Jew
ORCID: 0009-0005-3450-7699
Observed ORCID: 0009-0005-3450-7699
OpenAlex ID: A5037540065
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
2021 · Samuel D. Stampfer, Marissa-Skye Goldwater, et al. · Leukemia · 89
PDF
Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment
2020 · Scott Jew, Tiffany Chang, et al. · British Journal of Haematology · 24
PDF
Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients
2020 · Scott Jew, Sean Bujarski, et al. · British Journal of Haematology · 22
PDF
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma
2021 · Sean Bujarski, Marissa‐Skye Goldwater, et al. · European Journal Of Haematology · 12
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
2022 · Marissa-Skye Goldwater, Samuel D. Stampfer, et al. · Clinical Infection in Practice · 10
PDF
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients
2023 · Scott Jew, Sean Bujarski, et al. · Targeted Oncology · 8
Loss of anti‐spike antibodies following mRNA vaccination for COVID ‐19 among patients with multiple myeloma
2023 · Samuel D. Stampfer, Sean Bujarski, et al. · Cancer Reports · 5
PDF
Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab
2021 · David Yashar, Bernard Sean S. Regidor, et al. · Blood · 3
Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients
2019 · Scott Kristian Jew, Tiffany Chang, et al. · Blood · 3
Normalization of Serum B-cell Maturation Antigen Levels Predicts Progression Free and Overall Survival in Multiple Myeloma Patients Starting Treatment
2019 · Scott Jew, Tiffany Chang, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Outcomes of Triple Class Refractory Multiple Myeloma Patients: A Single Center Retrospective Study
2023 · Ryan Danis, David Yashar, et al. · Blood · 2
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study
2023 · Bernard Sean Regidor, Scott Jew, et al. · European Journal Of Haematology · 2
PDF
Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody
2022 · Bernard Sean Regidor, Dilawer Siddiqi, et al. · European Journal Of Haematology · 2
Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
2021 · Samuel D. Stampfer, Marissa-Skye Goldwater, et al. · Blood · 2
PDF
The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic
2023 · Scott Jew, Marissa-Skye Goldwater, et al. · American Journal of Clinical Pathology · 1
Serum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report
2024 · Ryan Danis, Bernard Regidor, et al. · Case Reports in Oncology
PDF
Works count: 16
Citation count: 188
H-index: 6
I10-index: 5
Year
Topic
Type